Enhancement of docetaxel solubility using binary and ternary solid dispersion systems

References

• Thomas VH, Bhattachar S, Hitchingham L, et al. The road map to oral bioavailability: an industrial perspective. Expert Opin Drug Metab Toxicol 2006;2:591–608
   PubMed Web of Science ®Google Scholar
• Chen J, Qiu L, Hu M, et al. Preparation, characterization and in vitro evaluation of solid dispersions containing docetaxel. Drug Dev Ind Pharm 2008;34:588–94
   PubMed Web of Science ®Google Scholar
• Moes JJ, Koolen SL, Huitema AD, et al. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). Int J Pharm 2011;420:244–50
   PubMed Web of Science ®Google Scholar
• Kuppens IE, Bosch TM, van Maanen MJ, et al. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol 2005;55:72–8
   PubMed Web of Science ®Google Scholar
• Gao K, Sun J, Liu K, et al. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm 2008;34:1227–37
   PubMed Web of Science ®Google Scholar
• van Waterschoot RA, Lagas JS, Wagenaar E, et al. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 2009;69:8996–9002
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62:6158–64
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis. Taxotere (docetaxel) injection. FDA/CDER; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020449s073lbl.pdf
   Google Scholar
• Sinha S, Ali M, Baboota S, et al. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech 2010;11:518–27
   PubMed Web of Science ®Google Scholar
• Chen C, Xie X, Li Y, et al. Influence of different polymers on crystallization tendency and dissolution behavior of cilnidipine in solid dispersions. Drug Dev Ind Pharm 2014;40:441–51
   PubMed Web of Science ®Google Scholar
• Forster A, Hempenstall J, Tucker, I, et al. The potential of small-scale fusion experiments and the Gordon-Taylor equation to predict the suitability of drug/polymer blends for melt extrusion. Drug Dev Ind Pharm 2001;27:549–60
   PubMed Web of Science ®Google Scholar
• Chiang PC, Cui Y, Ran Y, et al. In vitro and in vivo evaluation of amorphous solid dispersions generated by different bench-scale processes, using griseofulvin as a model compound. AAPS J 2013;15:608–17
   PubMed Web of Science ®Google Scholar
• Guzman HR, Tawa M, Zhang Z, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci 2007;96:2686–702
   PubMed Web of Science ®Google Scholar
• Jain S, Patel N, Lin S. Solubility and dissolution enhancement strategies: current understanding and recent trends. Drug Dev Ind Pharm 2014 . [Epub ahead of print]. DOI:10.3109/03639045.2014.971027
   Web of Science ®Google Scholar
• Hardung H, Djuric D, Ali S. Combining HME & solubilization: Soluplus® – the solid solution. Drug Deliv Technol 2010;10:20–7
   Google Scholar
• Shamma RN, Basha M. Soluplus®: a novel polymeric solubilizer for optimization of Carvedilol solid dispersions: formulation design and effect of method of preparation. Powder Technol 2013;237:406–14
   Web of Science ®Google Scholar
• Alhalaweh A, Alzghoul A, Kaialy W. Data mining of solubility parameters for computational prediction of drug-excipient miscibility. Drug Dev Ind Pharm 2014;40:904–9
   PubMed Web of Science ®Google Scholar
• Forster A, Hempenstall J, Tucker I, et al. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int J Pharm 2001;226:147–61
   PubMed Web of Science ®Google Scholar
• Thakral S, Thakral NK. Prediction of drug-polymer miscibility through the use of solubility parameter-based Flory-–uggins interaction parameter and the experimental validation: PEG as model polymer. J Pharm Sci 2013;102:2254–63
   PubMed Web of Science ®Google Scholar
• Taupitz T, Dressman JB, Buchanan CM, et al. Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs. Case example: itraconazole. Eur J Pharm Biopharm 2013;83:378–87
   PubMed Web of Science ®Google Scholar
• Mishra BB, Agarwal SK, Vardhan A. Amorphous form of docetaxel. 2008; WIPO Patent Application WO/2008/102374
   Google Scholar
• Mohsin S, Arellano IH, Choudhury NR, et al. Docetaxel epimerization in silicone films: a case of drug excipient incompatibility. Drug Test Anal 2014;6:1076–84
   PubMed Web of Science ®Google Scholar
• Garg MB, Ackland SP. Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. J Chromatogr B Biomed Sci Appl 2000;748:383–8
   PubMed Web of Science ®Google Scholar
• Greenhalgh DJ, Williams AC, Timmins P, et al. Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci 1999;88:1182–90
   PubMed Web of Science ®Google Scholar
• Kolter K, Karl M, Gryczke A. Hot-melt extrusion with basf pharma polymers extrusion compendium. Ludwigshafen, Germany: BASF; 2012
   Google Scholar
• Huynh L, Grant J, Leroux JC, et al. Predicting the solubility of the anti-cancer agent docetaxel in small molecule excipients using computational methods. Pharm Res 2008;25:147–57
   PubMed Web of Science ®Google Scholar
• Mazzaferro S, Bouchemal K, Gallard JF, et al. Bivalent sequential binding of docetaxel to methyl-beta-cyclodextrin. Int J Pharm 2011;416:171–80
   PubMed Web of Science ®Google Scholar
• Wu J, Shen Q, Fang L. Sulfobutylether-beta-cyclodextrin/chitosan nanoparticles enhance the oral permeability and bioavailability of docetaxel. Drug Dev Ind Pharm 2013;39:1010–9
   PubMed Web of Science ®Google Scholar
• Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs 2007;18:95–103
   PubMed Web of Science ®Google Scholar
• Zaske L, Perrin M-A, Leveiller F. Docetaxel: solid state characterization by X-ray powder diffraction and thermogravimetry. J Phys IV France 2001;11: Pr10-221-Pr10-6
   Google Scholar
• Tatini LK, Krishna Reddy KV, Someswara Rao N. Vapor-induced phase transformations in docetaxel. AAPS PharmSciTech 2012;13:548–55
   PubMed Web of Science ®Google Scholar
• Hancock BC, York P, Rowe RC. The use of solubility parameters in pharmaceutical dosage form design. Int J Pharm 1997;148:1–21
   Web of Science ®Google Scholar
• Marsac PJ, Shamblin SL, Taylor LS. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 2006;23:2417–26
   PubMed Web of Science ®Google Scholar
• Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci 2009;98:2549–72
   PubMed Web of Science ®Google Scholar
• Kestur US, Van Eerdenbrugh B, Taylor LS. Influence of polymer chemistry on crystal growth inhibition of two chemically diverse organic molecules. CrystEngComm 2011;13:6712–18
   Web of Science ®Google Scholar
• Raghavan SL, Trividic A, Davis AF, et al. Crystallization of hydrocortisone acetate: influence of polymers. Int J Pharm 2001;212:213–21
   PubMed Web of Science ®Google Scholar
• Saenger W, Müller-Fahrnow A. Cyclodextrins increase surface tension and critical micelle concentrations of detergent solutions. Angew Chem Int Ed Engl 1988;27:393–4
   Web of Science ®Google Scholar
• García-Río L, Méndez M, Paleo MR, et al. New insights in cyclodextrin: surfactant mixed systems from the use of neutral and anionic cyclodextrin derivatives. J Phys Chem B 2007;111:12756–64
   PubMed Web of Science ®Google Scholar
• Lee TW, Boersen NA, Yang G, et al. Evaluation of different screening methods to understand the dissolution behaviors of amorphous solid dispersions. Drug Dev Ind Pharm 2014;40:1072–83
   PubMed Web of Science ®Google Scholar
• Aucamp M, Odendaal R, Liebenberg W, et al. Amorphous azithromycin with improved aqueous solubility and intestinal membrane permeability. Drug Dev Ind Pharm 2014 . [Epub ahead of print]. DOI: 10.3109/03639045.2014.931967
   PubMed Web of Science ®Google Scholar
• Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006;29:278–87
   PubMed Web of Science ®Google Scholar